计算溶液所需的质量、体积或浓度。
为什么选择此级别
，适用于对基线干扰要求严格的色谱和分析工作流程。
储存与运输
2-8°C储存,干燥。低温运输 。请查阅批次 COA 获取详细规格。
质量文档
SDS、COA、产品数据表及规格说明书均可下载。可通过批号查询获取批次 COA。
文献证明
在色谱分析、有机合成和交叉偶联反应领域已被 0 篇同行评审文献引用。
概述
Momelotinib sulfate (CYT387 sulfate salt) is an ATP-competitive inhibitor of JAK1/JAK2 with IC 50 of 11 nM/18 nM, 10-fold selectivity versus JAK3 (IC 50 =155 nM).
In Vitro
Momelotinib sulfate (CYT387 sulfate salt) inhibits growth of Ba/F3- JAK2 V617F and human erythroleukemia (HEL) cells (IC 50 =1.5 μM) or Ba/F3- MPL W515L cells (IC 50 =200 nM), but has considerably less activity against BCR-ABL harboring K562 cells (IC 50 =58 μM) and FLT3 mutation harboring MV4-11 cells (IC 50 =3 μM). Proliferation of parental Ba/F3 cells (Ba/F3-wt) stimulated with IL-3 is inhibited with an IC 50 value of 1.4 μM, consistent with the established role of IL-3-dependent signaling in the parental cell line. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Momelotinib sulfate (CYT387 sulfate salt) at twice the dose used in disease model (50 and 100 mg/kg) has little to no effect on peripheral blood counts over a period of 8 weeks. Median plasma peak concentrations are 7.1 μM with the lower dose and 32.1μM with the higher dose, with a half-life of approximately 2 hours. Trough levels at 12 hours are 10nM for the 25 mg/kg and 900nM for the 50 mg/kg dose. At day 34 after transplantation, the mean white blood cell counts and hematocrit values of the entire cohort exceeded the normal range for Balb/c mice by more than 1 SD. At this point, 6 mice are sacrificed and subjected to autopsy. In the remaining animals, treatment is initiated with 25 mg/kg Momelotinib sulfate (CYT387 sulfate salt), 50 mg/kg Momelotinib sulfate (CYT387 sulfate salt), or vehicle, administered twice daily by oral gavage (12 mice per treatment group). A rapid drop of the white cell counts is apparent in both dose cohorts as early as 6 days after initiation of treatment and a decline of the hematocrit is apparent after 20 days. After oral dosing, Momelotinib sulfate (CYT387 sulfate salt) exhibits high plasma concentrations (C max = 40.4 μM; T max =4 h), with quantitative absolute oral bioavailability and an apparent half life of 2.4 h. The high oral bioavailability, can likely be partly ascribed to the low blood clearance of Momelotinib sulfate (CYT387 sulfate salt) (6.3 mL/min/kg) and therefore low susceptibility to hepatic first pass metabolism. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal administration
Mice On day 32 after bone marrow transplantation (when all mice exhibit severe leukocytosis and erythrocytosis), mice are assigned to 3 groups such that each group has equivalent average body weight and blood counts. Momelotinib (CYT387) is dissolved in NMP (120 mg/mL final; 1-methyl-2-pyrrolidinone, Chromasolv Plus). Subsequently, the Momelotinib/NMP mix is diluted with 0.14M Captisol to a concentration of 6 mg/mL and further diluted with 0.1M Captisol to a final concentration of 4 mg/mL. All 3 groups of mice (n=12 per group) are administered Momelotinib (CYT387) by oral gavage twice daily at 10- to 12-hour intervals from day 34 after bone marrow transplantation to day 82 (end of experiment). Mice receive NMP/Captisol without Momelotinib (CYT387) (0 mg/kg group), 25 mg/kg Momelotinib, or 50 mg/kg Momelotinib. At day 82 after bone marrow transplantation, all mice are euthanized for analysis except for 2 mice each from the 50 mg/kg and 25 mg/kg groups, which are taken off Momelotinib (CYT387) treatment and followed for 45 additional days. For assessment of the effects of Momelotinib (CYT387) on normal blood counts, naive Balb/c mice are administered vehicle control, 50 mg/kg, or 100 mg/kg Momelotinib (CYT387) in an identical fashion as described for the bone marrow transplant experimental mouse cohort. Peripheral blood is drawn at day 14, 28, 42, and 56 and levels of red cells, white cells, reticulocytes, granulocytes, lymphocytes, and monocytes are analyzed. aladdin has not independently confirmed the accuracy of these methods. They are for reference only.
Form:Solid
IC50& Target:JAK1 11 nM (IC 50 ) JAK2 18 nM (IC 50 ) JAK3 155 nM (IC 50 )
规格
别名
硫酸莫莫洛替尼
英文别名
A922136 | BENZAMIDE,N-(CYANOMETHYL)-4-[2-[[4-(4-MORPHOLINYL)PHENYL]AMINO]-4-PYRIMIDINYL]-,SULFATE (1:2) | BENZAMIDE, N-(CYANOMETHYL)-4-[2-[[4-(4-MORPHOLINYL)PHENYL]AMINO]-4-PYRIMIDINYL]-, SULFATE (1:2) | Sulfuric acid--N-(cyanomethyl)-4-{2-[4-(morpholin-4
英文名称
Momelotinib sulfate
生化机理
硫酸莫米替尼（CYT387 硫酸盐）是一种 ATP 竞争性 JAK1/JAK2 抑制剂，IC 50 为 11 nM/18 nM，对 JAK3（IC 50 =155 nM）的选择性为 10 倍。
储存条件
2-8°C储存,干燥
运输条件
低温运输
作用类型
抑制剂
名称和识别符
分子类型
小分子
IUPAC Name
N-(cyanomethyl)-4-[2-(4-morpholin-4-ylanilino)pyrimidin-4-yl]benzamide;sulfuric acid
INCHI
1S/C23H22N6O2.2H2O4S/c24-10-12-25-22(30)18-3-1-17(2-4-18)21-9-11-26-23(28-21)27-19-5-7-20(8-6-19)29-13-15-31-16-14-29;2*1-5(2,3)4/h1-9,11H,12-16H2,(H,25,30)(H,26,27,28);2*(H2,1,2,3,4)
InChi Key
XJGPMRGWDSQVTN-UHFFFAOYSA-N
Smiles
C1COCCN1C2=CC=C(C=C2)NC3=NC=CC(=N3)C4=CC=C(C=C4)C(=O)NCC#N.OS(=O)(=O)O.OS(=O)(=O)O
Isomeric SMILES
C1COCCN1C2=CC=C(C=C2)NC3=NC=CC(=N3)C4=CC=C(C=C4)C(=O)NCC#N.OS(=O)(=O)O.OS(=O)(=O)O
关联CAS
PubChem CID
分子量
610.62
技术文档
高级数据
系统学分类
分类树（Taxonomy Tree）
| 界（kingdom) | 有机化合物 |
|---|---|
| 超类（Superclass) | 有机杂环化合物 |
| 类（Class) | 二嗪类 |
| 亚类（Subclass） | 嘧啶和嘧啶衍生物 |
| 中间层级节点（Intermediate Tree Nodes） | 暂无 |
| 直接上位类(Direct Parent) | 苯基嘧啶 |
| 其他上位类（Alternative Parents） | 苯基吗啉 苯甲酰胺类 苯胺和取代苯胺 苯甲酰衍生物 二烷基芳胺 氨基嘧啶及其衍生物 有机硫酸 杂芳族化合物 氨基酸及其衍生物 仲羧酸酰胺 二烷基醚 氧环化合物 氮杂环化合物 仲胺 腈类 碳氢化合物衍生物 有机氧化物 |
| 分子骨架（Molecular Framework) | 芳香族杂单环化合物 |
| 取代基（Substituents） | 4-苯基嘧啶 - 氨基酸 - 氨基酸或其衍生物 - 氨基吡啶 - 苯胺或取代苯胺 - 芳香族杂单环化合物 - 氮杂环 - 苯甲酰胺 - 苯基化合物 - 苯甲酸或衍生物 - 苯甲酰 - 碳腈 - 羧酰胺基 - 羧酸衍生物 - 氰化物 - 二烷基醚 - 二烷基芳基胺 - 乙醚 - 杂芳香族化合物 - 烃衍生物 - 单环苯基基团 - Morpholine - 氰基化合物 - 有机硝基化合物 - 有机氧化物 - 有机氧化合物 - 有机磺酰胺 - 有机氮化合物 - 有机氧化合物 - 氧杂环 - 氧杂吡嗪烷 - 苯基异噁唑烷 - 醛基 - 醛基 - 硫代二羧酸 - 三芳基胺 |
| 描述（Description） | 该化合物属于苯并嘧啶类有机化合物。这类多环芳烃化合物通过碳碳键或氰基键将苯环与嘧啶环相连。嘧啶为六元环结构，由四个碳原子及位于1位和3位的两个氮原子中心构成。 |
| 外部描述符（External Descriptors） | 暂无 |
三维结构
交互式化学结构模型
化学和物理性质
溶解性
DMSO : 220 mg/mL (360.29 mM; Need ultrasonic) H2O : 100 mg/mL (163.77 mM; Need ultrasonic)
分子量
610.600 g/mol
XLogP3
氢键供体数Hydrogen Bond Donor Count
6
氢键受体数Hydrogen Bond Acceptor Count
15
可旋转键计数Rotatable Bond Count
6
精确质量Exact Mass
610.115 Da
单同位素质量Monoisotopic Mass
610.115 Da
拓扑极表面积Topological Polar Surface Area
269.000 Ų
重原子数Heavy Atom Count
41
形式电荷Formal Charge
0
复杂度Complexity
696.000
同位素原子数Isotope Atom Count
0
定义的原子立体中心计数Defined Atom Stereocenter Count
0
未定义的原子立体中心计数Undefined Atom Stereocenter Count
0
定义的键立体中心计数Defined Bond Stereocenter Count
0
未定义的键立体中心计数Undefined Bond Stereocenter Count
0
所有立体化学键的总数The total count of all stereochemical bonds
0
共价键合单元计数Covalently-Bonded Unit Count
3
质检证书（CoA,COO,BSE/TSE 和分析图谱)
C of A & Other Certificates(BSE/TSE, COO):
输入批号以搜索分析图谱:
溶液计算器
常见问题
本产品应如何储存？
请于2–8 °C、干燥条件下保存。请与干燥剂一同密封保存，本品对湿气敏感。
本产品如何运输？
本产品采用湿冰冷藏运输。收货后请立即拆包，并按上述储存条件保存。
本产品的 CAS 号、分子式和分子量是多少？
本产品的 CAS 号为 1056636-06-6，分子式为 C23H26N6O10S2，分子量为 610.62 g/mol。InChIKey XJGPMRGWDSQVTN-UHFFFAOYSA-N。
如何获取批次专用COA？
每个订单都会随附分析证书（COA），您也可以从账户订单历史中下载。如需订购前的COA，请联系您的客户代表，或使用PDP上的"申请COA"按钮——我们将提供代表性批次的COA。
产品仅提供给经过验证的企业、机构和合格的专业人员用于研发。不适用于人类、动物、诊断或治疗。
Copyright © 2023至今 上海阿拉丁生化科技股份有限公司 保留所有权利。
危险品化学品经营许可证（带存储）